Q2 2020 Earnings Call
[music].
To the second fiscal year 2020 you guys Mad earnings Conference call. My name is Christine and I'll be your operator for today's call.
At this time all participants are not listen only mode. Later, we'll conduct a question answer session. Please note. This conference is being recorded I would now like to turn the call over to Amy Wakeham, Vice President of Investor Relations and corporate Communications, Amy you may begin.
Great. Thank you Christine good afternoon, and good morning, everyone. Thanks for joining us and welcome to resume <unk> second quarter fiscal year 2020 earnings call. This call is being webcast live and the replay along with a copy of the earnings press release, and our updated investor presentation will be available on the Investor Relations section.
One of our corporate website later today.
Joining me on the call today to discuss our quarterly results our CEO Mitt.
CFO Brett.
Other ma'am.
<unk>.
Ladies and gentlemen, this is the operator, I apologize, but there'll be a slight delay in today's conference. Please hold the conference we're losing momentarily. Thank you for your patience.
Yes.
We continue to take share with our software solutions that enable increased therapy adherence with resupply programs, providing support to those who needed and with innovative new product introductions.
Customers with their wallets and they're voting for regimen.
The digital health technology to transform.
We have sold.
One.
Medical devices into the market and air solutions, our cloud based ecosystem now manages more than 12 million patients.
In the last 12 months, we have changed and improved over 15 million launch by providing a person with the resmon device or complete Resmed mask system to help embraced Bella and live better lives.
In addition, L. brightree and.
Digital Hill signal.
Everything that we have do here at reserve.
Okay propeller and a portfolio of.
Please allow us to better engage with our customers and partners.
Those providers.
James.
We are.
In our capable machine learning.
And grow this digit okay eager.
And.
Thanks to our ambitious forward looking goal of improved 250 lives in 25.
An important differentiator for resonate.
Ladies and gentlemen, this is the operator I apologize, possibly a slight delay in today's conference. Please hold the conference where Brazil momentarily. Thank you for your patience.
Hello Mr.
Okay.
Okay.
And any you may begin.
Great. Thank you everyone side for that we were having a few audio issues that weve re dial back in good afternoon, and good morning, everyone. Thanks for joining us and welcome to read led second quarter fiscal year 2020 earnings call. This call is being webcast live and the replay along with a copy of the earnings press release.
And our updated investor presentation will be available on the Investor Relations section of our corporate website later today.
Joining me on the call today to discuss our quarterly result.
Our CEO Mick Farrell as CFO Brett Sandercock.
Other members of management will be available during Q and a portion of the call.
During our call we will discuss several non-GAAP measures for a reconciliation of the non-GAAP measures. Please review the note to today's earnings press release.
And as a reminder, our discussion today may include forward looking statements.
Including but not limited to.
Expectations about Radnets future performance.
We believe these statements are based on reasonable assumptions. However, our actual results may differ you are encouraged to review our SEC filings for a discussion of the risk factors that could cause our actual results could differ materially from any forward looking statements made today with that I'd like to now turn the call over to Mick.
Great. Thanks, Amy and I'll go a little faster my prepared remarks, so we still have to unsecured I the spot design difficulties. Thanks, any and thank you to all shareholders for joining US today as we review results for residents second quarter fiscal year 2020 on todays call I will discuss our long term strategy. I'll, then review top level financial results some business follow.
Through the quarter and a few key milestones that will have nickel or the breadth, who will walk you through our financials in further detail our team achieved another quarter of strong revenue growth across the portfolio driven by supply performance in the last category, particularly in the us market with good performance across the 140 countries, where we provide.
Our solutions, we continue to take market share with our software solutions that enable increased the therapy adherence with resupply programs, providing support to those who needs and with our innovative new products customers of voting with their wallets and they have voting for resmed.
As the world's leading software driven medical device company, we are using digital health technology to transform the industry. We have sold nearly 11 million, 100% cloud Connectable medical devices into the market and air solutions, our cloud based ecosystem manages more than 12 million patients.
In the last 12 months, we have changed over 15 million lives, while providing a person with resume device or complete resmed mask system to help them breed better and live their lives.
In addition, our Brightree and matrix care software systems, I, hoping to manage 90 million more people outside the hospital.
Digital health technology is an integrated across everything that Resmon does airview my air propeller and a portfolio of other digital health solutions allow us to better engage with our customers and partners, including patients physicians providers payers and complete healthcare systems, we are.
Investing in advanced analytics, and expanding our capabilities in machine learning and machine intelligence. So that we can grow this digital health ecosystem at double digits on a volume basis, we will grow from just over 100 million lives improved with our healthcare products and solutions as we ended 2019 to our ambitious.
Forward looking goal of improving 250 million lives in 2025.
We now have over 5.5 billion minutes of respiratory medical data in the cloud and we are analyzing these data to derive actionable insights for the benefit of patients physicians providers and healthcare systems, our relentless focus on product and software innovation continues to set us apart from our competition.
We have massive upside opportunities ahead in sleep apnea in CRPD as well as in outside the hospital software to help patients live better quality lives to help patients and healthcare systems save money and to help achieve better management of chronic disease.
We believe that the future of healthcare is outside the hospital Thats, where Redmond completes today and Thats, where we are winning today, we have the right elements in place to achieve our strategy and to drive financial success as we provide market leading value to customers, let's say I'll briefly review our top level financial results.
We achieved another quarter of double digit revenue growth, we were up 14% in constant currency across our portfolio. This growth continues to be well balanced across our domestic us as well as our global product sales as well as from our software as a service businesses.
We continue to deliver operating leverage with non-GAAP operating profit growth of 21% Euro the need and non-GAAP diluted earnings per share of $1.21 cents.
I'd like to focus now on our call sleep apnea and respiratory care businesses.
In the devices category, we delivered a good quarter with year over year constant currency device growth of 8% globally supported by strong 9% device growth in the United States, Canada, and Latin America geographies as well as by improving Europe , Asia and rest of world growth, which was that.
6% constant currency in the device category.
We continue to face headwinds for device growth in France as a result of the 2018 in 2019 digital health related fleet upgrades, we expect the headwinds will begin to advice in the upcoming European Summer and we will start to return to market growth for devices in France during fish.
Full year 2021.
Underlying patient growth remains healthy around the globe and we continue to benefit from strong market dynamics with over 900 million people worldwide suffering from undiagnosed and Untraded sleep apnea.
Growth in the masks and accessories category of our business was incredibly strong during the quarter, we were up 16% constant currency globally in this category.
Well ahead of market growth rates, indicating that we gained significant market share with our lightest patient in advice innovations.
Removing the impact of some software within this category, we are still growing our global last franchise in the mid teens.
Flagship masks, the Airfit Ftwenty and the Airfit end 20 continue their growth across global markets. The success of these masks was mentored by continued good uptake of our more recent mask launches.
We have launched a steady rhythm of mask innovation over the past 15 months, we have just lapped the successful launch of the F 30 in the December quarter, and we will lap the launch of the entity the infinity Ari and the feasibility API during the coming 12 months. The F 30, I was lower.
Just over a week ago, combining the needs for patients in the freedom and the minimalist mask segments.
With our portfolio of solutions, we are ensuring that we have the right mask for every patient every time.
We are innovating and expanding our mass portfolio to offer comprehensive auctions for physicians and homecare providers and for the specific needs of the ultimate customer.
Thats the person, who Suffocates every night with sleep apnea.
We remain focused on driving innovation to made underserved customer needs, we are creating future products that a small quite a more comfortable and more customized to each person's nights.
Through digital health technology, such as the mine App, we're driving patient engagement with our therapy. So that people can enjoy the benefits of better operating and better slate.
We have well over 2 million patients using my ear and leveraging its insights and personalize feedback through coaching algorithms.
In parallel we are also ensuring that the cost of sleep apnea as a chronic disease can be better managed by physicians providers tires and healthcare systems.
Our digital end to end solutions combined with available 100% cloud connectivity as well as information provided to patients on their own smartphones are all leading to significant improvements in cost improvements in healthcare outcomes and improvements in quality of life. We believe cloud based software combined with will.
Leading medical devices can add value and improve both clinical outcomes as well as the patient experience.
On the partnership front, our joint venture with Virally is creating software solutions to help identify and engage and enroll people with sleep apnea on a journey to better sleeve and bit of rating.
We have commenced pilots in a handful of use cities to improve awareness identification and engagement with the importance of good sleeping breeding to overall health.
Philosophy is this the more person knows about how much zeiss appetite every now and the consequences of that suffocation on their overall health outcomes, the more likely they will seek solutions.
At a simplest level this partnership will drive incremental growth in our call sleep apnea business over the longer term and on a deeper level. This partnership will also allow resmon to participate in a broad chronic disease management platform covering sleep apnea cardiovascular disease diabetes men.
Ill health and beyond.
I'd like to now focus on our business in respiratory care. There were nearly 400 million people suffering from chronic obstructive pulmonary disease or CRPD worldwide.
We don't believe these people are well served by global healthcare systems today, and many CRPD patients frequent visitors to hospital emergency rooms, with admissions and frequent readmissions.
We have a vision to better manage CRP day patients through the use of technology with digital end to end solutions technology, such as our propeller platform helps how patients that communicated to it helps how they are encouraged in the medical care and it helps how folks are looked after as an individual.
Yes.
We believe that technology combined with world, leading medical equipment can add substantial value to improve both clinical outcomes and the patient experience.
We plan to offer a portfolio of solutions through all stages of CRT day progression, we will be there with stage one in stage two CVD patients as they commence in high yield pharmaceutical therapy managed by the propel a platform. We will be there was stage two in stage three CBD patients as they add portal on.
Engine therapy to their care, we will also be there with stage three and stage full CRP day patients as they commence noninvasive ventilation therapy, and ultimately life support ventilation therapy.
We will manage the person on one end to end digital health CRP day platform, helping the patient, helping their caregivers loved ones as well as helping their physicians and providers. So that they have the right information at the right time lowering costs and.
Improving outcomes.
Our team at propeller continues to progress the business as we move along the path from pilot trials to commercial partnerships with both pharmaceutical partners and healthcare systems.
The digital health opportunity within hailed respiratory medicine adherence will take time to build and we're making good progress in December propellant was included as the only chronic respiratory disease solution in express scripts first formulary for digital health solutions.
In November access for propel users was expanded to pharmacy services from Cvs.
From Walmart.
Kroger and from rights.
This was access directly from the Capella App via the mind pharmacy feature within that smartphone application.
We will update you on the milestones for propeller with partners in both pharma as well as healthcare systems as we move forward throughout 2020.
Finally, I'd like to focus on our software as a service business, we continue to integrate and optimize the out of hospital SaaS portfolio for long term growth, we're focused on leveraging our competitive advantage as the only strategic player competing with leading software solutions focused on home medical equipment provider.
As skilled nursing facilities as well as home health and hospice providers.
Our SaaS portfolio revenue grew 37% year on year. This last quarter benefiting from the matrix care acquisition that we lapped during November .
We estimate that the weighted average market growth rate of these sectors. We completed is in the high single digits.
Excluding the timing benefit of the matrix care acquisition and on a pro forma basis, our SaaS portfolio grew in line with market in Q2.
Our plan is to beat that market growth rate over the medium to long term.
As we reached the fourth anniversary of our Brightree acquisition here in 2020, we are achieving strong in our home medical equipment or HMH sector.
With our Brightree chain in Atlanta.
We just passed the one year anniversary with our matrix care acquisition in the quarter and we are increasing our investments in L. matrix care team up there in Minneapolis.
This investment is focused on new module introduction from matrix care platform. So that we can ensuring that we are able to grow and share ski now skilled nursing facility as well as home health hospice sectors as we move forward.
Yes, we're doing the hard work.
To make matrix care as successful as Brightree is in the Resmed portfolio and we have all the elements in place to do that.
It took around 24 months to see strong sustainable returns from our investments in R&D and our management team at Brightree. We think we can meet or beat that timelines for strong and sustainable returns from our matrix care investments that we are currently like.
Last quarter, we announced a collaboration with Sirona as the new preferred partner for home health and hospice software for soon as customers.
It is early days in that partnership and things are going very well, we've started to migrate existing home health and hospice customers to our matrix care solution.
Our sales team is actively engaged with cerners sales team with customers learning of the benefits of our matrix care home health and hospice software.
We are excited to drive growth from this partnership the rich interoperability between our two solutions will provide value for both cerner and resmed customers as well as their patients and residents.
I would like to take a moment to announce an exciting technology tuck in acquisition that we adjust in prices are complaining just this week Brightree signed an agreement to acquire a company cold Snap works networks is a privately held software company that provides patient contact management and workflow.
Optimization for sleep apnea resupply.
The combination of Brightree technology, and logical services with this news networks technology creates the largest resupply advice in the industry with end to end workflow automation.
For our HSD customers. The combination of these two technologies Brightree and networks will increase patient adherence and increase operational efficiency.
We expect the transaction to close very shortly the acquisition of snap works is expected to be neutral to our non-GAAP Resmed earnings per share. Initially however, we expect this acquisition will be accretive to non-GAAP earnings per share during fiscal year 2021.
In summary, we have the vision to transform and significantly improved software solutions across outside the hospital healthcare sectors.
We see a future where patients seamlessly transfer from Asia me to skilled nursing facilities to home health providers to hospice providers and beyond with reduced costs and increased efficiency, resulting in better system outcomes as well as a high quality of loss for the person.
In out of hospital care.
Before I turn the call over the breadth, let me close with this.
First half of fiscal year, 2020 was strong and we're well positioned to grow through the second half of fiscal 2020 and beyond.
The continued success of our masked and device portfolio, along with a solid pipeline of new products and new digital health solutions, covering sleep apnea CRPD and out of hospital software gives us confidence in continued growth as we move through the year.
We have position Resmed for the long term as a global leader in digital health driving topline and bottom line growth as we execute toward our 2025 strategy.
We are focused on our triple aim.
Just to slow chronic disease progression.
Second to reduce overall healthcare system costs and third to improve quality of life for the ultimate customer the patient.
With that I'll handle over the breadth in Sydney Phase remarks, and then we'll go to keep an eye breadth.
Great. Thanks Nate.
In my remarks today I'll provide an overview of our results for the second quarter on fiscal year 2020 .
As Mike noted, we had a strong quarter grew revenue for the December quarter was 736 million an increase of 30% over the prior year quarter.
Constant currency terms revenue increased by 14%.
Excluding revenue from acquisitions group revenue increased by 11% on a constant currency basis.
Hi, good caused a little bit our geographic distribution and excluding revenue from our software and service business.
Moving us, Canada, and Latin American countries were 408 million and increasing 14% over the prior year quarter.
Well in Europe , Asia, and other markets totaled 242 million, an increase of 5% over the prior year quarter.
However in constant currency terms housing and bond Europe Asia, and other markets increased by 8% over the prior year quarter.
So I can't revenue between products segments, US, Canada, and Latin America device sales were $204 million, an increase of 9% over the prior year quarter.
Masks and other sales were 204 million, an increase of 19% over the prior year quarter.
Revenue in Europe are you in other markets, because a 160 tuniu and increased 4% over the prior quarter, we're in constant currency terms and increased 6%.
Masked another solid year advisor and other markets were 79 million an increased 8% over the prior year quarter, we're in constant currency terms and increase or 11%.
Globally in constant currency terms device sales increased by 8% Walmart on the sales increased by 16% over the prior year quarter.
Software as a service revenue for the second quarter was 87 million an increase of 37% over the prior year quarter.
During the rest of my commentary today, I'll be referring to non-GAAP numbers, the non-GAAP measures adjust for the impact of amortization of acquired intangibles.
Discounting fair value adjustments to Fiveg deferred revenue litigation settlement expenses and acquisition related expenses.
We have provided full reconciliation of the longer to get numbers in our second quarter earnings press release.
Note that this quarter for GAAP reporting purposes, we are now reflecting the portion of Amazon version of acquired intangibles attributable to develop technology.
Constant styles, rather than being allocated to operating expenses.
We might this change along with a disclosure guidance.
This will mean disclose both GAAP and non-GAAP gross profit measures going forward.
We have included reconciliations both GAAP and non-GAAP gross profit and gross margin in our press release.
Going forward I will reference these non-GAAP metric is I believe it is the best measure and our underlying gross margin.
non-GAAP gross margin improved to 59.7% in the December quarter, compared to 59.1% Insein quarter last year.
Okay to the prior year non-GAAP gross margin increased by 60 basis points.
This was predominantly attributable to cyber product mix and manufacturing efficiencies, partially offset by typical declines in average selling prices.
Moving on the operating expenses Eris, Jay and I expenses for the second quarter 171 million, an increase of 6% over prior year quarter.
In constant currency terms egina expenses increased by 5%.
Excluding acquisitions is United States have increased by 2% on a constant currency basis.
As Jane I <unk> expenses as a percentage of revenue improved to 23.3% compared to 24.8% that we reported in the prior year quarter.
Looking forward subject to currency movements and taking into account recent acquisitions, we expect SGN I as a percentage of revenue to be in the range of 23% to 25% remaining three quarters of fiscal year 2020.
R&D expenses for the quarter were 50 mean and increasing 16% over the prior year quarter will in the constant currency basis, an increase of 18%.
Excluding acquisitions R&D expenses increased by focusing on a constant currency basis.
R&D expenses as a percentage of revenue was 6.8% contagious, 6.6% in the car you.
Well control subject currency movements, we expect R&D expenses as a percentage of revenue today in the range of 78% for the balance for fiscal year 2020 .
Total amortization of acquired intangibles was 20.6 means for the quarter.
Increase of 30% over the prior year quarter, reflecting the impact from our recent acquisitions.
Stock based compensation expense for the quarter was 14.1 year.
Our non-GAAP operating profits for the quarter was 209.5 million an increase of 21% over the prior year quarter.
Our non-GAAP net income for the quarter was 176.3 billion, an increase of 22% over the prior year quarter.
On a GAAP basis, our effective tax rate for the December quarter was 10.2%.
Well, our non-GAAP basis, 50 tax rate for the quarter with 11.6%.
Our tax rate was favorably impacted by a tax benefit of 20.3 billion associated with investing of employee share based compensation in particular, the tax deduction associated with the vesting of executive performance stock units in November .
Excluding the impact from this benefit our GAAP effective tax rate would have by 21.6% and our non-GAAP effective tax rate will bring 21.5%.
Looking forward, we estimate our effective tax rate for the second half of fiscal year, 2020 will bring the range of 19% to 21%.
non-GAAP diluted earnings per share for the quarter $1.21, an increase of 21% over the prior year quarter, while GAAP diluted earnings per share for the quarter over $1.10.
That diluted earnings per share will also favorably impacted by the tax benefit that I've just discussed.
Including the impact of this guy our non-GAAP earnings per share would have Blaine one dollarsseven sands.
Cash flow from operations for the second quarter was 69.9 million, reflecting robust underlying earnings.
Partially offset by the timing of tax payments with 111 million in tax heighten our second quarter.
Additionally, we made the payment for settlement to the U.S. Department of Justice of $40.6 million this quarter.
Capital expenditures for the quarter was 25.1 million depreciation and amortization for the December quarter totaled 45.5 million.
During the quarter, we paid dividends of 56.1 million.
We recorded equity losses of 6.9, I mean, your income statement in the December quarter associated with the virally joint venture.
We expect to record approximately 6 million equity losses, each quarter for the balance of fiscal year 2020 associated with a joint venture operations.
Our board of directors today declared a quarterly dividend of 39 cents per share.
At December 31, we had 1.3 billion in gross day, and 1.1 billion in net debt.
Our total assets were 4.4 billion balance sheet remains strong with modest debt levels.
Finally to recap our top line revenue was strong this quarter with growth across all major categories.
Margin expanded and our operating costs remain well controlled.
As a result, we are continuing continuing to drive operating leverage with Q2, non-GAAP operating profit up 21% year on year.
We are focused on driving operating results integrating assess acquisitions and ensuring we continue to invest in our strategic long term opportunities.
And with that I'll hand, the call backed lining.
Great. Thank you Brad ill now turn to the Q and a question in the call I would like to remind everyone can limit yourself to one question and let you have additional question. Please feel free to return to the Caulfield Christine we're now ready for the Q and a portion of the call.
Thank you we will now begin the question answer session. If you have a question. Please press Star then one on your Touchtone phone if you wish to be removed from the Q. Please press the pound signer heskey, if you're using a speaker phone you may mean, you pick up the handset firsts for before passing the numbers, we ask that as it.
A reminder, please limit yourself to one question. If you have another question you're welcome to hop back in the queue. Once again, if you have a question. Please press star and the number one and your Touchtone phone. Your first question comes from the line of Margaret Carryover from William Blair. Your line is open.
Hi, good afternoon guarantee in wanting to add spread out in Australia.
Thank you maybe the first one for.
For me is announced growth obviously continue to do very very well from that perspective, and so as we look at the last maybe 12 to 18 months can you give us a sense of the relevant factors new product launches, especially in white spaces, meaning that you learn and before and the resupply agreement taken a reference a little bit of JP.
Morgan market growth in general share, taking and the idea is as we look forward Adam how are the moving dynamics between known add those categories and how do you kind of adjust your strategy to keep performance. Thanks.
Yeah. Thanks for your question Margaret and as you know there's a number of factors contributing to this this is very strong mask growth that we had 16% constant currency on a global devices and even taking out some of the software just well up there in the mid teens you hit on pretty much all of them. This.
As an increased adherence that we're driving through our digital health solutions.
When we are achieving 87% adherence when the doctors using interview in the patients using my air and all the digital tax imply that drives up almost growth secondly, when his resupply patients have the opportunity if they want to to participate in getting a fresh mask as they're all mask.
Becomes used.
And we are partnering with Brightree connect and with Resmed resupply to provide that and the acquisition of snap works.
Help and then thirdly, and really importantly, these last three months the steady flow of four.
It really exciting you may ask innovations interestingly these mask innovations to replace a previous product, but to go after underserved or under met customer needs and we call. The minimalist category in the freedom category, where people move through a different positions during sleep Prime left right sleepers want afraid of mask and.
People, who had some cost for phobia all want small.
Larger masks goes for the minimalist category in the F 30 that we just launched is right in the heart of both of those so it's all the above contributing to this really strong Ross, we still think that the market growth right isn't the high single digits for masks and that we talk really good share. During this December quarter al job and challenges to keep driving all those things resupply.
Hi, adherence and mask innovation and we plan to do just that.
Thanks, Ken.
Your next pilot.
Your next question comes from the line of Matthew Mishan from Keybanc. Your line is open.
Great. Thank you for taking the questions.
Just a follow up on that more on the market share gains and masks.
Are you winning new new patients at a higher market share clip or are you able to convert existing sleep apnea patients from from competitors and getting them to switch.
Yeah, Matthew that's a really good question I'll hand that to Jim Hollingshead, the president of our slick division to walk through that.
Good morning, Matthew on down in Australia. So I hope you can hear me as well.
Can you just fine.
Yes, it's a combination of goal.
Well, we feel very confident in our overall position with mass the all right and we've had so many mouthwash it as Nick reference we met several mask launches in the last 15 months all of them and then successful launches and we now have a very wide portfolios. The wireless portfolio offering of NASA market. So we continue to take new patient share across all three mass categories.
And Im sure well.
We will likely also beginning competitors switching and theres less market data and then a lot having adequate we're very confident we're taking new patient share pretty successfully.
Thank you.
Yes.
Your next question comes from the line of Sean Laaman from Morgan Stanley . Your line is open.
Good morning make Honeywell.
My question relates to something you announced last quarter I Wonder if we give an update on how the some novartis deal with propeller, if there's any update there and how that might be tracking thanks.
Thanks, Sean what are we done talking to our core business or in our new software businesses about in individual.
Customers or partners until things public and moving along but there was a public data last quarter from outlook with Apollo trials with both GSK.
And novartis in the.
Propeller area looking at inhaled pharmaceutical medicines.
Look I think.
Those beauty all of us as I sort of described in the the opening remarks. The beauty of propeller is it provides an end to end platform to help us take care of people with chronic obstructive pulmonary disease, and so stage, one too with propel and take care of the patients ensure they have the medicine that their doctor prescribed for them, but also engage with that person because they.
Going to to progressive disease, they going to move from stage, one stage two stage three and stage for see as a day and so our goal with propel is not just to have a partnership with pharma company I was able to really creative platform, where we help into and management of a person as they move.
Through disease progression and it helps us engage with that person to help them at hedge their therapy, whether that therapies, the pharmaceutical inhaler or that there'll be is a portable oxygen concentrator all that therapy as they move forward is a non invasive but then a lighter or a lot support ventilator and so thats our goal with these partnerships as we hit milestones during 2000.
20 on the pharmaceutical side.
And as we hit milestones on the healthcare system side, we'll give updates on that but look yes, we did talk to the magnified trial that we still enrolling patients for.
With with Novartis, that's in its early days.
So we will give updates on the clinical data, but also importantly, commercial partnerships as I as I move forward through 2020. Thanks for your question Sean.
Yes, Thank you make.
Your next question comes from the line of time Dicamba from Citigroup. Your line is open.
Well good morning. My question just relates to be the increase in the SGN I, obviously, you got fantastic leveraged.
From that and we'll I think you've talked about previously, but the 2% underlying seem to I think thats of record low number for you and just give us a sense, perhaps of how that might look over the next six months and maybe going forward as shouldn't return back to those kind of mid single digit levels.
So I'll add that.
And with organic sitting here, yes, thanks, Thanks, Hi, John .
Okay. I was it was low this quarter, we didn't benefit certainly from a much lower litigation related expenses this quarter relative to last g., so that certainly motor right that growth right.
Vision.
Guidance I still think will revert back to their lines or 23 to 25 for the second half, which would suggest it will track.
In terms of growth Rice question and I.
Leasing the back half but.
Certainly held by some reduction will significant reduction litigation costs coming through this quarter launched last year was probably the single.
The biggest driver.
That said that selling moderated growth right.
And try to adjust for that in that kind of range at all given as a percentage revenue going forward to be better indicator I think.
That's helpful. Thanks.
Your next question comes from the line of Saul Hadassin journey from you be asked your line is open.
So all you may be on mute price.
No not can you hear me.
We can you now yes.
Great. Thanks.
Yes, just a question for Brett.
Great just on gross margin just wanted to give some color.
On the underlying sleep and respiratory care business.
Gross margin might have done X X acquisition contribution and usually provide an outlook for the rest of the fiscal year for gross margin as well can you just give us that some color there. Thank you.
Yes, I mean, nothing going for the second half being broadly consistent with where we are.
It would be an estimate on the gross margin.
Outlawed moving parts on that so that that will be our expectation.
If you look at the acquisitions, we did not.
Nitric economy halfway through the quarter, so fairly it's kind of fairly minimal impact this quarter. The big drivers of that you on you grossing app or expansion of their gross margin around the product mix.
And Thats really been driven by that that outperformance you, saying in mass growth and Thats.
Typically higher margins, what you'd see on the losses, so thats the biggest impact.
And then we feel thing manufacturing efficiencies.
Around logistics and so on as well.
So I continue to come through on gross margin.
Data to to be two big drivers this quarter.
Alright, thank you.
Your next question comes from the line of same story from Wilson HTM Limited your line is open.
Yes, hi, Thanks, just looking again back to us mass business for the Kansas from another angle you spoke about the adherence and recent targets have you mentioned the step up in the number of mass per patient to you say over the last talked about 18 months Mint loss reference point that off guard as maybe take on the to perpetuate usone observations around that.
Very useful thanks.
Yes, Shane Thanks for your question I think there is there's a whole portfolio of customers doing different levels of resupply in different countries around the world. If you take the example of that there's a government mandated requirement that you provide to masks to.
Two masks per patient per year.
And it's different in all the 140 countries you focused on the us growth which was strong.
And yes, the last public number we did talk about that was was 1.9 masks per patient per year, but look over the 5000 customers in the U.S., there's a broad spectrum of adoption of.
Brightree resupply Brightree connect Resmed resupply and technologies like Snapple works that we just acquired and so there's a broad range.
But Jim do you want to Jim Hollingshead, you want to provide any further color as to.
What you'd want to share on mask resupply metrics.
Yes. Thanks, Thanks, Nathan Thanks, Nathan Thanks Shane.
Just to add to the next I'd just say goal during the first one is.
The trend we don't we don't talk about the number of publicly obviously that the trend in the U.S. has been steadily slowly but steadily over the last several years I mean that we attribute that both due.
So the range of thinking they talked about earlier in the call showing better adherence tools that were providing our platforms.
Better masks lead to better adherence initially in there for better long term adherence and also the adoption of resupply.
Forms buyers unique customers. So the trend is slowly as though.
It's still well below Medicare and commercial parallels and so it's a good trend and there's still a lot of opportunity.
Okay. Thanks.
Your next question comes from the line of Steve Wynn from Evan and partners. Your line is open.
Hey, good afternoon.
My question is just on your staff businesses.
The growth right. There's one if you could help us.
Great construct but that growth right.
Particularly between metrics Kid and.
Gotcha and.
And perhaps you know as part of that to give us an update us too.
Your understanding of how those businesses are performing since they acquired.
I guess with reference to the EPS outlook.